HealthMerck, Moderna Positive Phase 3 Melanoma Vaccine
Merck and Moderna reported positive Phase 3 results for their personalized mRNA cancer vaccine intismeran autogene (V940/mRNA-4157) added to Keytruda in high-risk, surgically treated melanoma, showing longer recurrence-free survival and reduced distant metastasis with no new safety issues. The companies plan regulatory discussions and potential accelerated approval submissions, with data presentations at upcoming medical meetings and continued follow-up for overall survival.
Photo: Fletcher / Wikimedia Commons (CC BY 4.0)